Antidepressant Use During IVF: What We Know About Outcomes
Current data suggest that SSRI antidepressants do not meaningfully reduce IVF success, while untreated depression or anxiety may be associated with lower pregnancy and live birth rates.
Current data suggest that SSRI antidepressants do not meaningfully reduce IVF success, while untreated depression or anxiety may be associated with lower pregnancy and live birth rates.
While some antidepressants may affect the metabolism of tamoxifen into its active form, many antidepressants can be used safely in this population.
The recent FDA expert panel focused largely on the risks of SSRIs during pregnancy; however, medical organizations and experts support the important role of SSRIs and other medications in supporting maternal mental health.
The recent FDA expert panel focused largely on the risks of SSRIs during pregnancy; Dr. Freeman weighs in on the information provided in the report.
The recent FDA expert panel focused largely on the risks of SSRIs during pregnancy but ignored or diminished the risks associated with untreated depression in the mother.Â
The recent FDA expert panel focused largely on the risks of SSRIs during pregnancy but ignored or diminished the risks associated with untreated depression in the mother.Â
In a recent study from Mass General Hospital, researchers examined whether information included in the medical record at the time of discharge after delivery could help us to identify individuals at increased risk for postpartum depression.
Postpartum anxiety is a common and often under-recognized condition that affects a substantial proportion of new mothers.
This large cohort study from Taiwan indicates that the concomitant use of antidepressants and benzodiazepines during the first trimester is not associated with a substantial increase in risk for overall malformations.
There is evidence that depression itself can increase risk for preeclampsia. In women with more severe depression, treatment with an SSRI antidepressant may decrease risk.